-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO
More Synergies On The Go: New Wearable Ketamine Delivery Device by PharmaTher & CCBIO
PharmaTher Holdings Ltd. (OTC:PHRRF) continues on its path to becoming the leader in specialty ketamine products. A new product, developed in collaboration with the leader in design and manufacturing of wearable pen and auto injectors, CC Biotechnology Corporation, will combine PharmaTher's ketamine formulation with CCBIO's Felice Dose wearable delivery device. Clinical trials are expected to take place in the first months of 2023.
What The Innovation Implies For Ketamine Treatments
Ketamine, applied intravenously (IV) and intramuscularly (IM) for analgesia, sedation and anesthetic induction, is also emerging as a plausible option for treating various mental health, neurological and pain disorders, most notably Parkinson's disease.
As such, moving from IV and IM to wearable injection systems and microneedle patches could facilitate compliance and dose flexibility for both caregivers and patients. The new subcutaneous format might also improve safety and efficacy, reduce side effects, enhance patient comfort and adherence and reduce the time burden of treatment on patients and healthcare providers whether in hospital, clinic or at home.
"In addition, the current, evolving, and future therapeutic use of ketamine is dependent on the control of ketamine dosing to deliver pharmacokinetic profiles specific to each indication." said PharmaTher CEO Fabio Chianelli. "Therefore, our goal is to become a leader in specialty ketamine solutions, which include injectable, intravenous, microneedle patch and now a ketamine wearable device that each serve a unique solution to enable tailored pharmacokinetic profiles for various mental health, neurological, and pain disorders."
How It Would Work
CCBio's Felice Dose is a delivery motor system based on a body subcutaneous injector device that works for various drug volumes, concentrations and viscosities over variable and long-duration injections. It can deliver a stable dose of drug per unit time under discontinuous pressure, reducing the skin-swelling during injection and thus decreasing patient pain.
In addition, the system can adapt to the primary drug container, providing a very stable displacement unit for the drug, and the duration for filling and delivery can be programmed to suit the drug formulation.
In the present collaboration, CCBIO will be responsible for the development and clinical manufacturing activities and support PharmaTher's regulatory submissions towards the production and commercialization of the new wearable ketamine delivery device.
PharmaTher Holdings Ltd. (OTC:PHRRF) continues on its path to becoming the leader in specialty ketamine products. A new product, developed in collaboration with the leader in design and manufacturing of wearable pen and auto injectors, CC Biotechnology Corporation, will combine PharmaTher's ketamine formulation with CCBIO's Felice Dose wearable delivery device. Clinical trials are expected to take place in the first months of 2023.
PharmaTher控股有限公司。(場外交易代碼:PHRRF)繼續成為特製氯胺酮產品的領導者。與可穿戴筆和自動注射器的設計和製造領先者合作開發的一款新產品,CC生物技術公司,將把PharmaTher的氯胺酮配方與CCBIO的Felice劑量可穿戴遞送設備。臨牀試驗預計將在2023年的頭幾個月進行.
What The Innovation Implies For Ketamine Treatments
這項創新對氯胺酮治療意味着什麼
Ketamine, applied intravenously (IV) and intramuscularly (IM) for analgesia, sedation and anesthetic induction, is also emerging as a plausible option for treating various mental health, neurological and pain disorders, most notably Parkinson's disease.
靜脈注射(IV)和肌肉注射(IM)用於止痛、鎮靜和麻醉誘導的氯胺酮,也正在成為治療各種精神健康、神經和疼痛障礙的合理選擇,最引人注目的是帕金森氏病.
As such, moving from IV and IM to wearable injection systems and microneedle patches could facilitate compliance and dose flexibility for both caregivers and patients. The new subcutaneous format might also improve safety and efficacy, reduce side effects, enhance patient comfort and adherence and reduce the time burden of treatment on patients and healthcare providers whether in hospital, clinic or at home.
因此,從靜脈注射和注射到可穿戴注射系統和微針貼片可以促進照顧者和患者的依從性和劑量靈活性。這種新的皮下形式還可能提高安全性和有效性,減少副作用,提高患者的舒適度和依從性,並減少患者和醫療保健提供者在醫院、診所或家中接受治療的時間負擔。
"In addition, the current, evolving, and future therapeutic use of ketamine is dependent on the control of ketamine dosing to deliver pharmacokinetic profiles specific to each indication." said PharmaTher CEO Fabio Chianelli. "Therefore, our goal is to become a leader in specialty ketamine solutions, which include injectable, intravenous, microneedle patch and now a ketamine wearable device that each serve a unique solution to enable tailored pharmacokinetic profiles for various mental health, neurological, and pain disorders."
此外,氯胺酮目前、發展和未來的治療用法取決於對氯胺酮劑量的控制,以提供針對每個適應症的藥代動力學曲線。法瑪瑟説首席執行官法比奧·奇亞內利。因此,我們的目標是成為專業氯胺酮解決方案的領導者,這些解決方案包括注射、靜脈注射、微針貼片,現在是一種氯胺酮可穿戴設備,每種設備都提供獨特的解決方案,使各種精神健康、神經和疼痛障礙的定製藥代動力學曲線成為可能。“
How It Would Work
它是如何工作的
CCBio's Felice Dose is a delivery motor system based on a body subcutaneous injector device that works for various drug volumes, concentrations and viscosities over variable and long-duration injections. It can deliver a stable dose of drug per unit time under discontinuous pressure, reducing the skin-swelling during injection and thus decreasing patient pain.
CCBio‘s Felice劑量是一種基於人體皮下注射器裝置的輸送馬達系統,在可變和長期注射過程中,該裝置可用於不同的藥物體積、濃度和粘度。它可以在不連續的壓力下在單位時間內輸送穩定劑量的藥物,減少注射過程中的皮膚腫脹,從而減輕患者的痛苦。
In addition, the system can adapt to the primary drug container, providing a very stable displacement unit for the drug, and the duration for filling and delivery can be programmed to suit the drug formulation.
此外,該系統可以適應初級藥物容器,為藥物提供非常穩定的置換單元,並且灌裝和輸送的持續時間可以被編程以適應藥物配方。
In the present collaboration, CCBIO will be responsible for the development and clinical manufacturing activities and support PharmaTher's regulatory submissions towards the production and commercialization of the new wearable ketamine delivery device.
在目前的合作中,CCBIO將負責開發和臨牀製造活動,並支持PharmaTher就新型可穿戴氯胺酮輸送設備的生產和商業化提交的監管文件。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧